Quest for Growth cannot yet turn the tide in 2024

At 31 December 2024

• Net asset value per share: € 7.17 (at 31 December 2023: € 7.51)

• Share price: € 3.98 (at 31 December 2023: € 5.00)

• Discount of share price versus net asset value: 44.5% (at 31 December 2022: 33.4%)

Financial year 2024

• Net loss for the financial year: € -6,338,360 (€ -0.34 per ordinary share) against a loss of € -3,524,260 (€ -0.19 per ordinary share) for financial year 2023

• Lieve Creten succeeds Brigitte de Vet-Veithen as chairwoman of the board of directors after approval by the general meeting

• New direct co-investments in the companies Confo Therapeutics and Gradyent, together with the Capricorn Healthtech and Capricorn Digital Growth funds, respectively.

• Through the Capricorn ICT Arkiv fund, the participation in FEops was sold to Materialise, while Thryve is a new indirect investment through the Capricorn Digital Growth fund.

• Quest for Growth acts as a cornerstone investor in the new Capricorn Healthtech II fund.

• Rotation in the listed shares through 2024: Stratec, Mayr-Melnhof and LEM out. Harvia, Virbac, Andritz, Robertet and Init in.

Financial year 2025

• A takeover bid for Nexus in early November with a premium of 44% on the then stock market price had a positive impact on the result of € 1.8 million in 2024. When the takeover is formally completed (subject to approval of the bid), the entire stake in Nexus will be sold in 2025.

Results
Quest for Growth closed the 2024 financial year with a net loss of € -6,338,360. The return on equity was -4.50%. Quest for Growth's share price fell by 20.4% to a closing price of € 3.98 on 31 December 2024. The discount of the share price to the net asset value increased sharply to 44.5% at the end of 2024 compared to 33.4% at the end of 2023.